Effects of Synbiotics on FC and Other Contributing Factors

Effects of Synbiotics on Functional Constipation and Other Contributing Factors Among Constipated Individuals in Serdang, Selangor, Malaysia

Prevalence of functional constipation (FC) was first determined with 15.2% reported. Next, a 16-week randomised, double-blind, placebo-controlled study conducted to assess the improvement in functional constipation among the respective individuals by using synbiotic supplement. Throughout the intervention, it was reported that significant improvements for defecation frequency, Bristol Stool Form (BSF) scale, and Patients Assessment of Constipation Symptoms (PAC-SYM) scores were reported within synbiotic group (p < 0.001). However, no significant different was reported when compared both groups as placebo group was found to have significant within-group difference too. Placebo effect was suspected in this study.

Study Overview

• Status: Completed
• Conditions: Functional Constipation
• Intervention / Treatment: Dietary supplement: Synbiotic; Dietary supplement: Placebo

Detailed Description

Digestive system disease is the top ten principal causes of morbidity and mortality among Malaysians whereby functional constipation (FC) is the commonest functional gastrointestinal disorders (FGIDs) reported. Although numerous treatments are available, but over-the-counter drugs which have low product safety and possible toxicity were always given as the treatment option. Synbiotic have been well-studied to improve digestive health includes constipation. Thus, the objectives of this study were to determine the prevalence of FC and to evaluate the effects of synbiotic supplement on improving FC symptoms and contributing factors among constipated individuals in Serdang, Selangor. This study comprised of two parts which were screening and intervention part. The prevalence of functional constipation was relatively high in the study community. Synbiotic supplement was effective in the improvement of functional constipation symptoms, quality of life, and psychological factors. However, the positive improvement in placebo group indicated the existence of placebo effects which led to the improvement in quality of life and changes in psychological factors. Therefore, the current findings are useful information for future intervention in improving functional constipation symptoms.

• Study Type: Interventional
• Enrollment (Actual): 85
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Malaysian of either gender;
• 18 to 65 years old;
• Body mass index (BMI) 16.0 to 29.9 kg/m2;
• Positively diagnosed with functional constipation with Rome III-defined constipation module by the gastroenterologist

Exclusion Criteria:

• Vulnerable groups of pregnant and breastfeeding women;
• Physically or mentally handicapped individuals;
• Diagnosed with organic constipation (constipation associated with any neoplastic diseases, neuropathy or mechanical obstruction);
• Diagnosed with cardiovascular diseases, diabetes mellitus, cancer, neurological disease or other serious illnesses or severe medical complications;
• Faced alarm features indicative of colorectal cancer, metabolic disease and a history of gastrointestinal surgery.

To avoid the likelihood of co-intervention bias, the following respondents were excluded:

• On gastrointestinal medications;
• Consumed probiotics or synbiotic products more than once a week in two weeks preceding screening or during intervention period;
• Regularly used laxatives (more than once per week), used anticholinergics, anti-diarrheals, antibiotics or laxative in two weeks preceding screening or at any point during intervention.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Synbiotic; The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.	Dietary supplement: Synbiotic; 10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
Placebo Comparator: Placebo; Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.	Dietary supplement: Placebo; Non-active ingredients - Maltodextrins

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Defecation frequency	Defecation frequency was measured through participants' self reported defecation frequency in a week.	16 weeks
Stool types - Bristol Stool Form (BSF) Scale	BSF scale was used to characterise human stools to seven classifications using seven pictorial presentation of stool types.Type 1 stool shows the very slow transit time with longest time spent in the colon whereas Type 7 indicates the least time spent in the colon and has fast bowel transit time. Meanwhile, Type 4 is the most ideal stool type optimal colonic transit time.	16 weeks
Constipation symptoms - Patients Assessment of Constipation Symptoms (PAC-SYM)	PAC-SYM consists of a total of 12 questions includes abdominal symptoms, rectal symptoms, and stool symptoms. It comprised with a 5-point Likert scale ranging from 0 (Absent) to 4 (Very severe). The values of subscales and total scores for PAC-SYM were then computed as average item response within the scales and for the global score. Lower score obtained indicates less symptom severity.	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life - Patients Assessment of Constipation Quality of Life (PAC-QOL)	Quality of life was measured using Patients Assessment of Constipation Quality of Life (PAC-QOL). PAC-QOL consists of a total of 28 questions which was grouped into four domains include physical discomfort, psychological discomfort, worries and concerns, and satisfaction. It comprised with a 5-point Likert scale ranging from 0 (Not at all/None of the time) to 4 (Extremel/All of the time).The values of subscales and total scores for PAC-QOL scores were then computed as average item response within the scales and for the global score. Lower score point indicates a better quality of life of the respective participant.	16 weeks
Psychological factor - Depression, Anxiety, and Stress scale (DASS)	Psychological factor was measured using Depression, Anxiety, and Stress scale (DASS). DASS was used to self-report the severity of depression, anxiety and stress level. The questionnaire based on 4-point Likert scale, ranging from 0 (Did not apply to me at all) to 3 (Applied to me very much, or most of the time). The scores of depression, anxiety, and stress were summated for the relevant items followed by categorised to the severity of the condition. Lower score point indicates a less severity of the respective participant.	16 weeks

Collaborators and Investigators

• Sponsor: Universiti Putra Malaysia

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2015
• Primary Completion (Actual): April 1, 2016
• Study Completion (Actual): January 1, 2018

Study Registration Dates

• First Submitted: October 16, 2018
• First Submitted That Met QC Criteria: November 5, 2020
• First Posted (Actual): November 6, 2020

Study Record Updates

• Last Update Posted (Actual): November 6, 2020
• Last Update Submitted That Met QC Criteria: November 5, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: Prevalence; synbiotic; Rome III criteria; functional constipation; Bristol Stool Form Scale; defecation frequency; PAC-SYM; PAC-QOL; randomised controlled trial (RCT)
• Additional Relevant MeSH Terms: Signs and Symptoms, Digestive; Constipation
• Other Study ID Numbers: SynFC_001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No